The Tunisian pharmaceutical industry produces a significant volume of medications, covering approximately 80% of the country's needs. However, when measured in value, the coverage drops to 60%. This 20-point difference has sparked interest in understanding the industry's structure and its actual economic impact. According to Tarek Hammami, representative of the National Syndicate of the Pharmaceutical Industry, 43 manufacturers produce medications for human use in Tunisia.
The industry's production capacity is substantial, but its economic weight cannot be solely measured by the number of medications manufactured. The discrepancy between volume and value coverage suggests that locally produced medications may be more affordable, while higher-value products might be imported. Hammami provided these insights during an interview on the Radio nationale's Le Paysage économique program on October 9, 2026.
The Tunisian pharmaceutical industry employs over 9,000 people and generates more than 320 million dinars in annual exports. These numbers highlight the sector's industrial and export capabilities, although its recent progress remains unclear. The industry also has the potential for technological modernization, with four Tunisian factories expected to upgrade, and plans to develop the use of artificial intelligence.
To better understand the industry's situation, it would be essential to compare locally produced and imported medications, their respective values, and the research and development capacities. This information would help assess the industry's ability to increase the value of its production. The sector's future growth depends on its capacity to enhance its economic impact.
The industry's structure and market dynamics are crucial in understanding the gap between volume and value coverage. However, specific data on therapeutic categories, import distribution, and average prices are not readily available. This lack of information makes it challenging to determine the exact reasons behind the discrepancy.
Tarek Hammami's statements emphasize the significance of the pharmaceutical industry in Tunisia, with 43 manufacturers producing medications for human use. The industry's substantial production capacity and export potential underscore its importance in the country's economy. Nevertheless, a more in-depth analysis is required to understand the sector's challenges and opportunities.
Moving forward, the industry's focus should shift towards measuring the value produced and exploring ways to increase it. This might involve investing in research and development, modernizing production facilities, and developing high-value products. By addressing these challenges, the Tunisian pharmaceutical industry can strengthen its position in the market and contribute more significantly to the country's economy.
Key points
- The Tunisian pharmaceutical industry covers 80% of its medication needs in volume but only 60% in value.
- The industry employs over 9,000 people and generates more than 320 million dinars in annual exports.
- The sector's future growth depends on its ability to increase the value of its production.
